Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up

被引：13
|
作者：
McClure, Tess [1 ,2 ]
Cui, Wanyuan [2 ,3 ]
Asadi, Khashayar [4 ]
John, Thomas [3 ]
Testro, Adam [1 ,2 ]
机构：
[1] Austin Hlth, Gastroenterol, Heidelberg, Vic, Australia
[2] Univ Melbourne, Med, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Austin Hlth, Anat Pathol, Heidelberg, Vic, Australia
来源：
BMJ OPEN GASTROENTEROLOGY | 2020年 / 7卷 / 01期
关键词：
autoimmune biliary disease; cancer immunobiology; cholestatic liver diseases; drug toxicity; liver function test;
D O I：
10.1136/bmjgast-2020-000487
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Long-term follow-up of children and adolescents with primary sclerosing cholangitis and autoimmune sclerosing cholangitis
    Vratislav Smolka
    Eva Karaskova
    Oksana Tkachyk
    Kvetoslava Aiglova
    Jiri Ehrmann
    Kamila Michalkova
    Michal Konecny
    Jana Volejnikova
    [J]. Hepatobiliary & Pancreatic Diseases International, 2016, 15 (04) : 412 - 418
  • [2] Long-term follow-up of children and adolescents with primary sclerosing cholangitis and autoimmune sclerosing cholangitis
    Smolka, Vratislav
    Karaskova, Eva
    Tkachyk, Oksana
    Aiglova, Kvetoslava
    Ehrmann, Jiri
    Michalkova, Kamila
    Konecny, Michal
    Volejnikova, Jana
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2016, 15 (04) : 412 - 418
  • [3] Hepatobiliary sarcoidosis presenting as sclerosing cholangitis: Long-term follow-up
    Maambo, Emily
    Brett, Allan S.
    Vasudeva, Rajeev
    Burns, Ronald G.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (12) : 3363 - 3365
  • [4] Primary sclerosing cholangitis in children: A long-term follow-up study
    Feldstein, AE
    Perrault, J
    El-Youssif, M
    Lindor, KD
    Freese, DK
    Angulo, P
    [J]. HEPATOLOGY, 2003, 38 (01) : 210 - 217
  • [5] Primary sclerosing cholangitis in children: A long-term follow-up study
    Feldstein, AE
    Angulo, P
    El-Youssef, M
    Freese, DK
    Harmsen, WS
    Lindor, KD
    Perrault, J
    [J]. GASTROENTEROLOGY, 2002, 122 (04) : A645 - A646
  • [6] Hepatobiliary Sarcoidosis Presenting as Sclerosing Cholangitis: Long-Term Follow-Up
    Emily Maambo
    Allan S. Brett
    Rajeev Vasudeva
    Ronald G. Burns
    [J]. Digestive Diseases and Sciences, 2007, 52 : 3363 - 3365
  • [7] Nivolumab-induced sclerosing cholangitis: A case report and literature review
    McClure, T.
    Cui, W.
    Testro, A.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 37 - 37
  • [8] Small-duct primary sclerosing cholangitis: A long-term follow-up study
    Angulo, P
    Maor-Kendler, Y
    Lindor, KD
    [J]. HEPATOLOGY, 2002, 35 (06) : 1494 - 1500
  • [9] Disease burden in primary sclerosing cholangitis in the Netherlands: A long-term follow-up study
    van Munster, Kim N.
    Mol, Bregje
    Goet, Jorn C.
    van Munster, Sanne N.
    Weersma, Rinse K.
    de Vries, Annemarie C.
    van der Meer, Adriaan J.
    Inderson, Akin
    Drenth, Joost P.
    van Erpecum, Karel J.
    Boonstra, Kirsten
    Beuers, Ulrich
    Dijkgraaf, Marcel G. W.
    Ponsioen, Cyriel Y.
    [J]. LIVER INTERNATIONAL, 2023, 43 (03) : 639 - 648
  • [10] Nivolumab-Induced Secondary Sclerosing Cholangitis with Deterioration Despite Immunosuppression
    Anderson, Brady
    Dawe, David E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : E205 - E206
12345